Stock listing
6XC Stock Price, News, Filings & Events — Soleno Therapeutics, Inc.
Selected listing: 6XC · GETTEX · EUR · DE
This page tracks Soleno Therapeutics, Inc.'s 6XC:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 6XC:GETTEX. 6XC:GETTEX is the stock-level entry point for investors researching Soleno Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Soleno Therapeutics, Inc. (Ticker: SLNO) is a public company based in the United States, with a market capitalization of approximately $2.76 billion. The company focuses on developing innovative therapies for rare diseases. Soleno is committed to advancing its research and product pipeline to address unmet medical needs.
- Ticker
- 6XC:GETTEX
- Asset type
- Stock
- Market cap
- $2.76B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- GETTEX
- Currency
- EUR
Soleno Therapeutics, Inc. 6XC:GETTEX stock context
This page tracks Soleno Therapeutics, Inc.'s 6XC:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 6XC:GETTEX. 6XC:GETTEX is the stock-level entry point for investors researching Soleno Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Soleno Therapeutics, Inc. (Ticker: SLNO) is a public company based in the United States, with a market capitalization of approximately $2.76 billion. The company focuses on developing innovative therapies for rare diseases. Soleno is committed to advancing its research and product pipeline to address unmet medical needs.
Latest news from Soleno Therapeutics, Inc.
Soleno Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
May 7, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
April 15, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
February 25, 2026
Soleno Therapeutics, Inc. earnings calls
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call
February 25, 2026 · Replay with transcript and chapters
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call
May 7, 2025 · Replay with transcript and chapters
Research Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for 6XC:GETTEX.
Soleno Therapeutics, Inc. company profile
View the public company page for Soleno Therapeutics, Inc. on 6ix.
Soleno Therapeutics, Inc. news
Read company news and market updates connected to Soleno Therapeutics, Inc..
Soleno Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Soleno Therapeutics, Inc..
Alternate listings
SLNO:NASDAQ
US · USD
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
SLNO:BOATS
US · USD
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
A3DS0P:LS
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
A3DS0P:LSX
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
1SLNO:MIL
IT · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
6XC:TRADEGATE
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
6XC:FWB
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
6XC:SWB
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
6XC:DUS
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.
6XC:MUN
DE · EUR
Alternate listing for Soleno Therapeutics, Inc.; the primary context on this page is 6XC:GETTEX.